Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSKVX000000009151
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
GSKVX000000009151 is a viral vector vaccine candidate developed by GSK for the treatment of chronic hepatitis B (CHB). It utilizes the Chimpanzee Adenovirus 155 (ChAd155) platform to deliver genetic sequences encoding three essential hepatitis B virus (HBV) antigens: the surface antigen (HBsAg), the core antigen (HBcAg), and a truncated version of the viral polymerase. The vaccine is designed to stimulate a potent, multi-specific T-cell response aimed at clearing HBV-infected hepatocytes and achieving a "functional cure," defined as the sustained loss of HBsAg. In clinical trials, GSKVX000000009151 is typically evaluated as part of a heterologous prime-boost immunotherapy regimen (often referred to as GSK3903371) that includes an MVA-HBV viral vector vaccine and an adjuvanted protein vaccine (GSK3528869A).
- Other names
- Chimpanzee Adenovirus 155-HBVGSK HBV viral vector vaccine
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on GSKVX000000009151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSKVX000000009151.